Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

One in 10 people may have resistance to GLP-1 diabetes drugs (opens in a new tab)

med.stanford.edu · 2026-04-10

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

  • 5 supported
  • 1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

One claim overstates the study. Five of six check out.

  • 5 supported
  • 1 overstated
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedIn a meta-analysis of three clinical trials with 1,119 participants, carriers of PAM variants were less responsive to GLP-1 receptor agonists and less likely to reach HbA1c targets after six months.View evidenceHide evidence

As statedabout a quarter of non-carriers reached the recommended HbA1c target after six months, compared with 11.5% with p.S539W and 18.5% with p.D563G

Why this verdict

The profile supports a meta-analysis of 1,119 participants across three clinical cohorts showing significantly attenuated HbA1c reduction and lower HbA1c <7% attainment for p.S539W carriers. But the story frames the result more broadly as applying to PAM variant carriers generally, while the supplied abstract-level evidence specifically emphasizes p.S539W; the p.D563G target-attainment figure and the six-month timing are not verifiable from the profile. The profile also describes cohorts/meta-analysis rather than simply three clinical trials.

1

Study evidence

Carriers of the PAM p.S539W risk allele had a significantly attenuated HbA1c reduction following GLP-1RA therapy compared with non-carriers.−0.69% (carriers) vs −1.24% (non-carriers); p = 0.025; reported 44% relative loss of glycemic benefit

“Glycemic response to GLP-1RAs was evaluated in a meta-analysis of 1,119 participants across three cohorts (IMI-DIRECT, GoDARTS, PRIBA), with comparative assessment of sulphonylurea, metformin, and DPP-4 inhibitor response.”
Claim 2 of 6SupportedA new study by Stanford Medicine scientists and collaborators says GLP-1 receptor agonists might not work as well for people with certain genetic variants.View evidenceHide evidence

As statedmore than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists; roughly 10% of the general population carry the variants

Why this verdict

The abstract-level profile supports the core claim that PAM genotype, especially p.S539W, is associated with attenuated glycemic response to GLP-1 receptor agonist therapy in people with T2D. The story’s hedged wording (“might not work as well”) is consistent with the observational pharmacogenomic evidence. The contextual prevalence/drug-use figures are not verifiable from the supplied paper profile.

1

Study evidence

Carriers of the PAM p.S539W risk allele had a significantly attenuated HbA1c reduction following GLP-1RA therapy compared with non-carriers.−0.69% (carriers) vs −1.24% (non-carriers); p = 0.025; reported 44% relative loss of glycemic benefit

“Glycemic response to GLP-1RAs was evaluated in a meta-analysis of 1,119 participants across three cohorts (IMI-DIRECT, GoDARTS, PRIBA), with comparative assessment of sulphonylurea, metformin, and DPP-4 inhibitor response.”
Claim 3 of 6SupportedThe variants, which researchers say are carried by roughly 10% of the general population, are associated with “GLP-1 resistance,” where GLP-1 levels are higher but less biologically effective.View evidenceHide evidence

As statedroughly 10% of the general population

Why this verdict

The supplied profile supports that carriers of hypomorphic PAM alleles had elevated circulating GLP-1 and reduced endogenous GLP-1 sensitivity, especially p.S539W, which is consistent with an associational description of GLP-1 resistance. However, the roughly 10% population frequency is not verifiable from the abstract-level profile, and any literal causal reading of “cause” would outrun the human observational evidence.

1

Study evidence

Carriers of the PAM p.S539W allele demonstrated a 52% reduction in serum PAM amidation activity relative to matched non-carriers.52% reduction

“PAM amidation activity, postprandial GLP-1 levels, and the incretin effect were measured in carriers of PAM T2D-risk alleles and matched non-carriers from the Oxford Biobank in a prospective observational study”
2

Study evidence

Carriers of p.S539W and p.D563G alleles demonstrated reductions in serum PAM amidation activity (reported as 52% and 20% reductions, respectively).p.S539W: −52%; p.D563G: −20%

“...and in Danish cohorts.”
Claim 4 of 6SupportedThe study, published April 10 in Genome Medicine, focused on blood sugar regulation and combined human experiments, mouse studies, and diabetes drug trial data.View evidenceHide evidence

As stateddecadelong, international effort

Why this verdict

The profile supports that the study combined human physiologic carrier-versus-non-carrier analyses, mouse Pam loss-of-function experiments, and a clinical meta-analysis of GLP-1RA glycemic response. The focus on glycemic/GLP-1 physiology is supported. The publication date and journal name are bibliographic details not independently verifiable from the supplied scientific profile.

1

Study evidence

Carriers of the PAM p.S539W allele demonstrated a 52% reduction in serum PAM amidation activity relative to matched non-carriers.52% reduction

“PAM amidation activity, postprandial GLP-1 levels, and the incretin effect were measured in carriers of PAM T2D-risk alleles and matched non-carriers from the Oxford Biobank in a prospective observational study”
2

Study evidence

Carriers of p.S539W and p.D563G alleles demonstrated reductions in serum PAM amidation activity (reported as 52% and 20% reductions, respectively).p.S539W: −52%; p.D563G: −20%

“...and in Danish cohorts.”
Claim 5 of 6SupportedIn participants with and without a PAM variant, the researchers reported higher circulating GLP-1 in variant carriers but no evidence of higher biological activity or faster blood sugar reduction.View evidenceHide evidence

As statedblood sampled every five minutes for four hours after a sugary solution

Why this verdict

The abstract-level human data support higher circulating GLP-1 in PAM variant carriers and reduced, not increased, GLP-1 sensitivity for p.S539W carriers. That aligns with the story’s statement that higher GLP-1 did not translate into higher biological activity. The specific sampling schedule and detailed blood-glucose-reduction wording are not available at this evidence depth.

1

Study evidence

Carriers of the PAM p.S539W allele demonstrated a 52% reduction in serum PAM amidation activity relative to matched non-carriers.52% reduction

“PAM amidation activity, postprandial GLP-1 levels, and the incretin effect were measured in carriers of PAM T2D-risk alleles and matched non-carriers from the Oxford Biobank in a prospective observational study”
2

Study evidence

Carriers of p.S539W and p.D563G alleles demonstrated reductions in serum PAM amidation activity (reported as 52% and 20% reductions, respectively).p.S539W: −52%; p.D563G: −20%

“...and in Danish cohorts.”
Claim 6 of 6SupportedMouse experiments suggested PAM loss leads to GLP-1 resistance, including faster gastric emptying and reduced response to GLP-1 receptor agonist treatment.View evidenceHide evidence

Why this verdict

The mouse findings in the profile directly support accelerated gastric emptying in inducible whole-body Pam knockout mice and refractoriness to exendin-4, a GLP-1 receptor agonist, along with impaired downstream pyloric cAMP signaling. In this experimental animal context, the story’s claim that PAM loss suggested GLP-1 resistance is supported.

1

Study evidence

PamKO mice displayed accelerated gastric emptying as measured by a paracetamol absorption assay.

“Inducible whole-body Pam knockout mice were generated; gastric emptying was assessed by paracetamol absorption assay with and without exendin-4.”
2

Study evidence

cAMP signaling downstream of the GLP-1 receptor in pylorus tissue is impaired in Pam whole-body knockout mice.

“...impaired cAMP signaling downstream of the GLP-1 receptor in the pylorus.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Specificity of drug-response effect: the paper profile reports no genotype-associated response differences for sulphonylureas, metformin, or DPP-4 inhibitors.

    The story focuses on GLP-1 receptor agonists and does not mention the comparator drug-class analyses, which are material because they support selectivity of the pharmacogenomic association.

    From Multi-cohort meta-analysis of clinical cohorts (genotype-stratified pharmacogenomic analysis)

  • Important human-evidence limitation: the human carrier physiology evidence is observational and does not by itself establish causality.

    The story includes caveats about uncertain mechanism and weight-loss effects, but it does not explicitly state that the human carrier-versus-non-carrier evidence is observational and therefore limited for causal inference.

    From Prospective observational carrier vs matched non-carrier study (Oxford Biobank); candidate variant carrier-vs-non-carrie

3 things the story did carry across
  • Human carrier-versus-non-carrier physiology: hypomorphic PAM alleles were associated with reduced serum PAM amidation activity, elevated circulating GLP-1, and reduced endogenous GLP-1 sensitivity, especially for p.S539W.
  • Clinical pharmacogenomic result: in a 1,119-participant meta-analysis, p.S539W carriers had attenuated HbA1c response to GLP-1 receptor agonists and were less likely to achieve HbA1c <7%.
  • Mouse mechanistic evidence: inducible whole-body Pam knockout mice had accelerated gastric emptying, reduced response to exendin-4, and impaired pyloric GLP-1R-linked cAMP signaling.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataPAM genotype (especially p.S539W) is a pharmacogenomic determinant of glycemic response to GLP-1 receptor agonist therapy in people with T2D; effects are selective versus other drug classes.Multi-cohort meta-analysis of clinical cohorts (genotype-stratified pharmacogenomic analysis)Expand

In plain English

Meta-analysis of 1,119 participants from three clinical cohorts (IMI-DIRECT, GoDARTS, PRIBA) found that carriers of the PAM p.S539W T2D-risk allele had a significantly attenuated glycemic response to GLP-1 receptor agonist (GLP-1RA) therapy (smaller HbA1c reduction and lower likelihood of achieving HbA1c <7%), while responses to sulphonylureas, metformin, and DPP-4 inhibitors did not differ by PAM genotype.

Key findings

  • Carriers of the PAM p.S539W risk allele had a significantly attenuated HbA1c reduction following GLP-1RA therapy compared with non-carriers.−0.69% (carriers) vs −1.24% (non-carriers); p = 0.025; reported 44% relative loss of glycemic benefit
  • No differences in glycemic response by PAM genotype were observed for sulphonylureas, metformin, or DPP-4 inhibitors in the comparative analyses.
“Glycemic response to GLP-1RAs was evaluated in a meta-analysis of 1,119 participants across three cohorts (IMI-DIRECT, GoDARTS, PRIBA), with comparative assessment of sulphonylurea, metformin, and DPP-4 inhibitor response.”
2human in vivoHypomorphic T2D-risk alleles in PAM reduce PAM amidation activity and alter GLP-1 physiology in humans (postprandial GLP-1 levels and incretin effect/GLP-1 sensitivity).Prospective observational carrier vs matched non-carrier study (Oxford Biobank)Expand

In plain English

In a prospective observational study of carriers of PAM T2D-risk alleles (p.S539W, p.D563G) and matched non-carriers from the Oxford Biobank, investigators measured serum PAM amidation activity, postprandial GLP-1 levels, and the incretin effect. Carriers showed reduced PAM amidation activity (p.S539W: 52% reduction; p.D563G: 20% reduction), elevated circulating GLP-1, and, for p.S539W carriers, an 18% reduction in endogenous GLP-1 sensitivity.

Key findings

  • Carriers of the PAM p.S539W allele demonstrated a 52% reduction in serum PAM amidation activity relative to matched non-carriers.52% reduction
  • Carriers of the PAM p.D563G allele demonstrated a 20% reduction in serum PAM amidation activity relative to matched non-carriers.20% reduction
“PAM amidation activity, postprandial GLP-1 levels, and the incretin effect were measured in carriers of PAM T2D-risk alleles and matched non-carriers from the Oxford Biobank in a prospective observational study”
What this piece can’t prove
  • Prospective observational carrier-versus-non-carrier design reported; observational studies do not by themselves establish causality.
  • Abstract does not provide sample sizes, detailed statistical adjustments, or full assay methods for the Oxford Biobank cohort.
3human in vivoHypomorphic T2D-risk alleles in PAM reduce PAM amidation activity and alter GLP-1 physiology in humans (postprandial GLP-1 levels and incretin effect/GLP-1 sensitivity).candidate variant carrier-vs-non-carrier analysisExpand

In plain English

In additional Danish human cohorts (separately from the Oxford Biobank), carriers of hypomorphic PAM T2D-risk alleles (p.S539W, p.D563G) were assessed versus matched non-carriers for serum PAM amidation activity, postprandial GLP-1 levels, and measures of incretin/GLP-1 sensitivity. Across the human data reported in the abstract, carriers showed reduced PAM amidation activity, elevated circulating GLP-1, and reduced endogenous GLP-1 sensitivity (notably an 18% reduction in p.S539W carriers). The abstract does not provide cohort-specific numerical breakdowns for the Danish cohorts.

Key findings

  • Carriers of p.S539W and p.D563G alleles demonstrated reductions in serum PAM amidation activity (reported as 52% and 20% reductions, respectively).p.S539W: −52%; p.D563G: −20%
  • Human carriers exhibited elevated circulating GLP-1 levels.
“...and in Danish cohorts.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vivo animalWhole-body Pam loss-of-function in mice perturbs gastric emptying and GLP-1R pathway function (including diminished response to GLP-1RA exendin-4 and impaired downstream signaling in pylorus).Inducible whole-body Pam knockout with paracetamol absorption gastric emptying assay ± exendin-4 challengeExpand

In plain English

Inducible whole-body Pam knockout (PamKO) mice were generated and assessed for gastric emptying using a paracetamol absorption assay with and without the GLP-1 receptor agonist exendin-4. PamKO mice showed accelerated gastric emptying that did not respond to exendin-4; concomitantly, impaired cAMP signaling downstream of the GLP-1 receptor was observed in the pylorus.

Key findings

  • PamKO mice displayed accelerated gastric emptying as measured by a paracetamol absorption assay.
  • Accelerated gastric emptying in PamKO mice was refractory to the GLP-1 receptor agonist exendin-4 (exendin-4 did not reverse the accelerated gastric emptying).
“Inducible whole-body Pam knockout mice were generated; gastric emptying was assessed by paracetamol absorption assay with and without exendin-4.”
What this piece can’t prove
  • The inducible whole-body Pam knockout model may have systemic effects beyond pyloric tissue; the abstract does not delineate tissue-specific contributions.

2 further details could not be confirmed from the summary.

5ex vivo animalWhole-body Pam loss-of-function in mice perturbs gastric emptying and GLP-1R pathway function (including diminished response to GLP-1RA exendin-4 and impaired downstream signaling in pylorus).ex vivo pylorus cAMP assayExpand

In plain English

In Pam whole-body knockout mice, cAMP signaling downstream of the GLP-1 receptor in pylorus tissue is impaired, consistent with reduced GLP-1R pathway function reported in the study.

Key findings

  • cAMP signaling downstream of the GLP-1 receptor in pylorus tissue is impaired in Pam whole-body knockout mice.
“...impaired cAMP signaling downstream of the GLP-1 receptor in the pylorus.”
What this piece can’t prove
  • Unclear assay methodology and sample size preclude assessment of robustness and reproducibility.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

In patients with type 2 diabetes, which GLP-1 receptor agonist results in the greatest HbA1C reduction?

Evidence-Based Practice · 2020 · Crossref

Source (opens in a new tab)
Candidate

RWD40 DECLINING BASELINE HBA1C AT GLP-1 RECEPTOR AGONIST INITIATION IN U.S. ADULTS WITH TYPE 2 DIABETES, 2015-2024

Value in Health · 2026 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.